Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

ZacksSCR May. 12 at 9:15 PM

$QNRX: Targeting Completing Recruitment for NS Trial by YE26 https://buff.ly/qben8oW

0 · Reply

revuelto May. 11 at 4:00 PM

$QNRX will need to wait for the def 14a in q3 but I would assume the free float is now much closer to the shares outstanding ads count, ~2m.……trading is thin right now but once someone starts aggressively slapping the bid, this will move exponentially higher..classic illiquid nanocap dynamics 😀

1 · Reply

TraderBuckNKY May. 11 at 2:51 PM

$QNRX something positive is brewing....

0 · Reply

revuelto May. 11 at 1:58 PM

$QNRX trading as if this is a lost cause…but for how much longer? The stage it’s at isn’t exactly extremely bullish but it’s not extremely bearish either…so yeah, I am staying in 😀..

0 · Reply

Telll May. 7 at 1:10 PM

$QNRX 🙌🏻 https://investors.quoinpharma.com/node/10231/pdf

0 · Reply

SuperGreenToday May. 7 at 10:56 AM

$QNRX

0 · Reply

revuelto May. 5 at 9:57 PM

$QNRX a ‘run’ here would be perfect…it’s got all the classic ingredients...the science checks out…now I see whether management surprises us for once or sticks to form😀

0 · Reply

InvestingSpaceman May. 4 at 8:17 PM

$QNRX $IMNN CO

0 · Reply

InvestingSpaceman May. 4 at 7:42 PM

$GLXY $QNRX $BYND squueeeze

0 · Reply

InReview May. 4 at 2:14 PM

$QNRX Lucid Capital Markets initiated Quoin Pharmaceuticals coverage with Buy and target of $30.

0 · Reply

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

2026-05-04T10:11:14.000Z - 9 days ago

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

Apr 30, 2026, 8:30 AM EDT - 13 days ago

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 28, 2026, 12:02 PM EDT - 14 days ago

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

2026-04-28T13:41:57.000Z - 14 days ago

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

Apr 28, 2026, 8:30 AM EDT - 15 days ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

2026-03-27T11:06:44.000Z - 6 weeks ago

Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global

2026-03-25T13:40:52.000Z - 6 weeks ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-03-25T13:35:56.000Z - 6 weeks ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

2026-03-25T12:55:48.000Z - 7 weeks ago

Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA

Mar 25, 2026, 8:30 AM EDT - 7 weeks ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

Mar 19, 2026, 8:30 AM EDT - 7 weeks ago

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

2026-03-11T12:38:45.000Z - 2 months ago

Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

Mar 11, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

2026-02-26T13:53:53.000Z - 2 months ago

Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program

2026-02-17T15:25:48.000Z - 3 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-02-17T15:15:27.000Z - 3 months ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

2026-01-27T13:36:50.000Z - 3 months ago

Quoin announces submission to Japanese MHLW for ODD for QRX003

Jan 27, 2026, 8:30 AM EST - 3 months ago

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

2026-01-20T13:46:13.000Z - 4 months ago

Quoin files Breakthrough Medicine Designation with SFDA for QRX003

Jan 20, 2026, 8:30 AM EST - 4 months ago

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

2025-11-11T13:35:24.000Z - 6 months ago

Quoin announces achievement of rapamycin target loadings

2025-11-07T21:55:18.000Z - 6 months ago

Quoin Pharmaceuticals files to sell 10.05M ADSs for holders

2025-11-06T13:36:03.000Z - 6 months ago

Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year

2025-11-06T13:35:38.000Z - 6 months ago

Quoin Pharmaceuticals sees cash runway into 2027

Nov 6, 2025, 8:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

2025-10-28T12:40:50.000Z - 7 months ago

Quoin recruits three additional patients to Netherton Syndrome study

2025-10-21T12:35:22.000Z - 7 months ago

Quoin Pharmaceuticals announces FDA granted ODD to QRX003

2025-10-15T14:30:20.000Z - 7 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

2025-10-15T14:25:18.000Z - 7 months ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

Oct 10, 2025, 9:24 AM EDT - 7 months ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Provides Product Portfolio Update

May 20, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 1 year ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 1 year ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 25, 2024, 4:05 PM EDT - 2 years ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

May 9, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 4:10 PM EDT - 2 years ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 13, 2024, 4:05 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Feb 14, 2024, 9:00 AM EST - 2 years ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Dec 13, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Nov 9, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 8, 2023, 5:46 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 3, 2023, 8:41 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Oct 24, 2023, 9:32 AM EDT - 2 years ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

ZacksSCR May. 12 at 9:15 PM

$QNRX: Targeting Completing Recruitment for NS Trial by YE26 https://buff.ly/qben8oW

0 · Reply

revuelto May. 11 at 4:00 PM

1 · Reply

TraderBuckNKY May. 11 at 2:51 PM

$QNRX something positive is brewing....

0 · Reply

revuelto May. 11 at 1:58 PM

$QNRX trading as if this is a lost cause…but for how much longer? The stage it’s at isn’t exactly extremely bullish but it’s not extremely bearish either…so yeah, I am staying in 😀..

0 · Reply

Telll May. 7 at 1:10 PM

$QNRX 🙌🏻 https://investors.quoinpharma.com/node/10231/pdf

0 · Reply

SuperGreenToday May. 7 at 10:56 AM

$QNRX

0 · Reply

revuelto May. 5 at 9:57 PM

$QNRX a ‘run’ here would be perfect…it’s got all the classic ingredients...the science checks out…now I see whether management surprises us for once or sticks to form😀

0 · Reply

InvestingSpaceman May. 4 at 8:17 PM

$QNRX $IMNN CO

0 · Reply

InvestingSpaceman May. 4 at 7:42 PM

$GLXY $QNRX $BYND squueeeze

0 · Reply

InReview May. 4 at 2:14 PM

$QNRX Lucid Capital Markets initiated Quoin Pharmaceuticals coverage with Buy and target of $30.

0 · Reply

V2IcedPriate May. 1 at 11:57 PM

$QNRX known runner

0 · Reply

V2IcedPriate May. 1 at 11:56 PM

$QNRX

0 · Reply

TraderBuckNKY May. 1 at 2:33 PM

$QNRX ASHBURN, Va. , April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026 , before the market opens on Thursday, May 7, 2026 . The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the first quarter of 2026.

0 · Reply

TheGodsMustBeCrazy May. 1 at 2:43 AM

$QNRX

0 · Reply

focafoca99 Apr. 30 at 12:57 PM

$QNRX Quoin will provide a corporate update and first-quarter 2026 financial results on May 14.

0 · Reply

TwongStocks Apr. 30 at 12:31 PM

$QNRX Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announce-corporate-update-and-first

0 · Reply

squiggleburp Apr. 29 at 8:05 PM

$QNRX Hey Scooby, we breaking out?

0 · Reply

focafoca99 Apr. 28 at 6:41 PM

$QNRX provided a clinical and regulatory update centered on its lead rare-disease programs.

0 · Reply

revuelto Apr. 28 at 3:37 PM

$QNRX algos will do what algo do…but will you algo out before this algos? 😀

0 · Reply

prismmarketview Apr. 28 at 2:46 PM

(NASDAQ: $QNRX) @QuoinPharma announced today that its QRX009 topical rapamycin program is positioned to be in active clinical testing across four rare disease indications by year-end 2026. The first investigator-led study is expected to begin in Pachyonychia Congenita, led by Professor Edel O'Toole of Queen Mary University of London, a globally recognized clinical expert in the field. Additional investigator-led studies in Gorlin Syndrome and Tuberous Sclerosis Complex are planned later this year. Quoin also remains on track to submit an IND to the U.S. FDA for QRX009 in an additional indication in Q3 2026. https://prismmarketview.com/quoin-pharmaceuticals-expands-qrx009-platform-with-multi-indication-clinical-roadmap-for-2026/

0 · Reply

revuelto Apr. 28 at 1:05 PM

$QNRX review the pipeline breadth and external kol validation…mc ~$10M justified? Won’t stay in this price range, ‘grab’ it while you can is essentially what it is 😀

0 · Reply

TwongStocks Apr. 28 at 12:33 PM

$QNRX Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-0 • Initiate Investigator Led Clinical Study in Pachyonychia Congenita in Q3 • Quoin is also planning to initiate investigator-led clinical studies in both Gorlin Syndrome (GS) and Tuberous Sclerosis Complex (TSC) later this year. • In addition to the Investigator Led Studies Company is Targeting to File Investigational New Drug Application to US Food and Drug Administration for QRX009 for an additional indication in Q3 2026

0 · Reply

Market Cap	11.33M
Revenue (ttm)	0.00
Net Income (ttm)	-15.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,400
Avg Vol	112,430
Day's Range	N/A - N/A
Shares Out	1.80M
Stochastic %K	36%
Beta	1.61
Analysts	Strong Sell
Price Target	$29.67